Lund, Sweden, 2013-01-22 16:26 CET (GLOBE NEWSWIRE) --
Bone Scan Index (BSI) is valuable when monitoring the effects of the therapy given to prostate cancer patients. This was one of the take home messages from an international symposium held at the University of Würzburg. The great interest stresses the need for multidisciplinary collaboration, and shows the international potential of BSI measurements.
On Wednesday, January 9, 2013, Professor Anders Bjartell from Skåne University was the keynote speaker at a BSI-seminar held at the University of Würzburg, Germany. The seminar was well attended, both by urologists and by nuclear medicine physicians.
Anders Bjartells lecture, titled "The Urologist's View on Bone Scan Index for Interpretation of Skeletal Metastases in Prostate Cancer Patients.", described the benefits and the clinical significance of BSI, all from the perspectives of a urologist. Anders Bjartell stated that the automatically calculated and reliably BSI-value could be very useful in monitoring prostate cancer patients.
Dr. Kristina Tägil, employee at EXINI, then highlighted the technical aspects of the automatic calculation of BSI in her lecture "Automated BSI - how does it work?”.
The two lectures attracted great interest among the assembled participants.
“The great interest in multidisciplinary seminars of this nature clearly shows the international potential importance of the automated calculation of Bone Scan Index.”, says Magnus Aurell, CEO EXINI Diagnostics AB.
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of radiology images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 400 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 19A, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, email@example.com, www.exini.com